Publications
- Expensive medicinal Products needs to be financed differently: the function of the Dutch Policy rule is still not optimal.
Marja Pronk, Bart van der Lelie, Carla Schoonderbeek.
Medisch Contact 2007;43: 1768-70.
- Medicinal Products with added value: Innovation of the Dutch price reference system is urgently needed.
Marja Pronk, Carla Schoonderbeek.
Medisch Contact 2007;15: 632-5.
- The reimbursement structure of in- and out-patient market access: two different systems on one pillow.
Marja H. Pronk, Carla J.R.A. Schoonderbeek, Gouke J. Bonsel.
TSG 2005; 3: 145-151.
- Out-patient drug policy by clinical assessment rather than financial constraints? The gate-keeping function of the out-patient drug-reimbursement system in the Netherlands.
Marja H. Pronk, Gouke J. Bonsel.
Eur J Health Econom 2004; 5:2740-277.
- The budget control function of the Dutch Price Reference System.
M.H. Pronk, G.J. Bonsel, A. van der Kuy.
Ned Tijdschrift Geneesk 2002; 37:1729-33.
- Introduction to the Pharmacoeconomics of Herbal Medicines.
Smet PAGM de, Bonsel G, Kuy van der, Hekster YA, Pronk MH, Brorens MJA, Lockefeer JHM, Nuijten MJC.
Pharmacoeconomics 2000; 18 (11):1-7.
- Reporting Format for Ecnomic Evaluation Part II : Focus on modelling studies.
Nuijten MJC, Pronk MH, Brorens MJA, Hekster YA, Lockefeer JHM
Pharmacoeconomics 1998; 14 (3):259-68.
- Reporting format on Economic Evaluation Part 1 : Application to the Dutch Healthcare System. Nuijten MJC, Brorens MJA, Hekster YA, Kuy van der, Lockefeer JHM, Smet PAGM de, Bonsel GJ and Pronk MH.
Pharmacoeconomics 1998;14(2):159-63.
- Evaluation of the therapeutic value of drugs: efficacy, applicability, effectiveness and efficiency.
Pronk MH, Bonsel GJ, Brorens MJA, Hekster YA, Kuy A. van der, Smet PAGM de.
Ned Tijdsch Geneesk 1998 (142);697-701.
- Proposal for standardised reporting of economic evaluations.
Pronk MH, Brorens MJA, Eschuazier AM, Hardens M, Hekster YA, Kuy A. van der, Lockefeer JHM, Smet PAGM de.
Pharm Weekbl 1997; 132(9):268-71.